Background and aims: Motor fluctuations are a major challenge in advanced Parkinson's disease (PD), often managed using add‐on therapies such as catechol‐O‐methyl transferase (COMT) or monoamine oxidase‐B (MAO‐B) inhibitors. This evidence concerns the gene MAOB and Parkinson disease.